Skip to Content
Merck
  • Chronic electrical stimulation with a suprachoroidal retinal prosthesis: a preclinical safety and efficacy study.

Chronic electrical stimulation with a suprachoroidal retinal prosthesis: a preclinical safety and efficacy study.

PloS one (2014-05-24)
David A X Nayagam, Richard A Williams, Penelope J Allen, Mohit N Shivdasani, Chi D Luu, Cesar M Salinas-LaRosa, Sue Finch, Lauren N Ayton, Alexia L Saunders, Michelle McPhedran, Ceara McGowan, Joel Villalobos, James B Fallon, Andrew K Wise, Jonathan Yeoh, Jin Xu, Helen Feng, Rodney Millard, Melanie McWade, Patrick C Thien, Chris E Williams, Robert K Shepherd
ABSTRACT

To assess the safety and efficacy of chronic electrical stimulation of the retina with a suprachoroidal visual prosthesis. Seven normally-sighted feline subjects were implanted for 96-143 days with a suprachoroidal electrode array and six were chronically stimulated for 70-105 days at levels that activated the visual cortex. Charge balanced, biphasic, current pulses were delivered to platinum electrodes in a monopolar stimulation mode. Retinal integrity/function and the mechanical stability of the implant were assessed monthly using electroretinography (ERG), optical coherence tomography (OCT) and fundus photography. Electrode impedances were measured weekly and electrically-evoked visual cortex potentials (eEVCPs) were measured monthly to verify that chronic stimuli were suprathreshold. At the end of the chronic stimulation period, thresholds were confirmed with multi-unit recordings from the visual cortex. Randomized, blinded histological assessments were performed by two pathologists to compare the stimulated and non-stimulated retina and adjacent tissue. All subjects tolerated the surgical and stimulation procedure with no evidence of discomfort or unexpected adverse outcomes. After an initial post-operative settling period, electrode arrays were mechanically stable. Mean electrode impedances were stable between 11-15 kΩ during the implantation period. Visually-evoked ERGs & OCT were normal, and mean eEVCP thresholds did not substantially differ over time. In 81 of 84 electrode-adjacent tissue samples examined, there were no discernible histopathological differences between stimulated and unstimulated tissue. In the remaining three tissue samples there were minor focal fibroblastic and acute inflammatory responses. Chronic suprathreshold electrical stimulation of the retina using a suprachoroidal electrode array evoked a minimal tissue response and no adverse clinical or histological findings. Moreover, thresholds and electrode impedance remained stable for stimulation durations of up to 15 weeks. This study has demonstrated the safety and efficacy of suprachoroidal stimulation with charge balanced stimulus currents.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-Glial Fibrillary Acidic Protein (GFAP) Antibody, serum, Chemicon®
Isoflurane, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Monoclonal Anti-Neurofilament 200 (Phos. and Non-Phos.) antibody produced in mouse, clone N52, ascites fluid
Sigma-Aldrich
Anti-Glutamine Synthetase Antibody, clone GS-6, clone GS-6, Chemicon®, from mouse